---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-036277"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2026-09-11T11:48:13+00:00"
generated_at: "2026-09-11T11:50:45.240889+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics corrects 3-month BCVA data in OPGx-BEST1 Cohort 1; mixed outcomes across 5 patients

## Summary
- Corrected 3-month BCVA changes: 101-101 treated eye +12 letters, fellow eye +4 letters.
- 101-104 treated +1 letter, fellow -7; 102-101 treated -10, fellow -8 letters.
- 102-102 treated +2 letters, fellow -5; 101-106 treated +6, fellow +2 letters.
- Revision fixes immaterial logMAR-to-ETDRS translation error on Slide 15; high-res microperimetry grids added to appendix.

## SEC filing metadata
- accession: 0001140361-26-036277
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2026-09-11T11:48:13+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036126036277/0001140361-26-036277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036126036277/ef20081922_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-036277
- JSON: https://secwatch.observer/filing/0001140361-26-036277.json
- Plain text: https://secwatch.observer/filing/0001140361-26-036277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.